AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 2 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Wikipedia Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,627 followers.

RT @FrontOncology: New research: AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study: Background Aldo-keto reduc…

20 Jul 2022

Reply Repost Favourite

New research: AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study: Background Aldo-keto reductase 1B10 (AKR1B10) is a secretory protein that is upregulated in breast cancer.Objective This case-controlled pilot study… https://t.c

25 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.